State of Wisconsin Investment Board Acquires New Position in ANI Pharmaceuticals, Inc. (ANIP)
State of Wisconsin Investment Board acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $281,000. State of Wisconsin Investment Board owned approximately 0.05% of ANI Pharmaceuticals as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of ANIP. First Manhattan Co. grew its stake in ANI Pharmaceuticals by 35.3% during the 2nd quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock valued at $17,615,000 after purchasing an additional 98,300 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in ANI Pharmaceuticals by 94.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 177,525 shares of the specialty pharmaceutical company’s stock worth $8,789,000 after buying an additional 86,011 shares during the last quarter. Kennedy Capital Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $4,069,000. Renaissance Technologies LLC lifted its holdings in ANI Pharmaceuticals by 19.5% during the 1st quarter. Renaissance Technologies LLC now owns 278,000 shares of the specialty pharmaceutical company’s stock worth $13,764,000 after buying an additional 45,300 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in ANI Pharmaceuticals by 25.5% during the 1st quarter. Bank of America Corp DE now owns 197,224 shares of the specialty pharmaceutical company’s stock worth $9,764,000 after buying an additional 40,111 shares during the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.
ANIP has been the topic of a number of research analyst reports. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Guggenheim reaffirmed a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. Canaccord Genuity initiated coverage on ANI Pharmaceuticals in a report on Monday, July 31st. They set a “buy” rating and a $60.00 target price on the stock. BidaskClub downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $65.33.
TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/15/state-of-wisconsin-investment-board-acquires-new-position-in-ani-pharmaceuticals-inc-anip.html.
Shares of ANI Pharmaceuticals, Inc. (ANIP) opened at 50.08 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $42.23 and a one year high of $69.85. The company has a market cap of $582.83 million, a P/E ratio of 109.58 and a beta of 3.10. The company has a 50 day moving average price of $46.66 and a 200 day moving average price of $48.01.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. During the same period in the previous year, the company posted $1.11 earnings per share. The company’s quarterly revenue was up 43.0% compared to the same quarter last year. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.